Key Highlights
- JSPR traded near $0.70 at last closing, valuing the company at roughly $23 million.
- Jasper completed an all-stock Acquisition of Kira Pharmaceuticals on July 16, 2026.
- An August 14, 2026 update disclosed a roughly $132 million PIPE financing, extending cash runway into the second half of 2028.
- Its lead antibody, briquilimab, has shown positive data in chronic spontaneous urticaria through the BEACON program.
Jasper Therapeutics entered 2026 as a struggling clinical-stage biotech and has since reinvented itself through dealmaking. The stock still trades below $1, near $0.70 with a market Capitalization around $23 million, but the company behind ticker JSPR looks materially different than it did in the spring, following an acquisition and a sizable financing. That transformation, more than any technical "setup," is the real story for shareholders weighing the recent drift lower.
Company and Latest Development
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is an immunology-focused biotech whose lead antibody, briquilimab (an anti-CD117 monoclonal), has been studied in chronic spontaneous urticaria (CSU) through its BEACON program. After the board launched a review of strategic alternatives on June 1, 2026, the company moved quickly. On July 16, 2026, Jasper completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined entity focused on biologic therapies for immunologically driven disorders. In its August 14 update, Jasper said it had closed a PIPE financing of non-voting convertible preferred stock generating approximately $132 million, funding operations into the second half of 2028.
What Is Driving Attention Around JSPR?
The recent drift lower in a sub-$1 stock has no single confirmed daily catalyst, and the shares had earlier drawn a Nasdaq notice regarding continued-listing standards. But the substantive attention stems from the corporate overhaul. The Kira acquisition and the roughly $132 million financing together recapitalized a company that only months earlier was weighing asset sales and had been downgraded by at least one analyst. Positive BEACON data in CSU, reported earlier in 2026, added clinical context to the strategic pivot and helped frame the newly enlarged pipeline.
Key Numbers and Company Position
Verified figures center on the recapitalization. The August financing brought in approximately $132 million via non-voting convertible preferred stock, with management indicating a cash runway into the second half of 2028, a dramatic improvement for a company whose Equity market capitalization sat near $23 million and whose shares traded around $0.70. Earlier in the year, Jasper reported sizable quarterly net losses typical of a clinical-stage biotech, underscoring why the financing and Merger were pivotal to its survival and strategy.
What Could Come Next?
The combined company's clinical roadmap is the key watch item: progress for briquilimab in CSU and any pipeline additions from the Kira combination, including further BEACON or open-label extension data and regulatory interactions. Investors may also monitor how the enlarged entity deploys its strengthened balance sheet, whether it addresses the sub-$1 share price to maintain Nasdaq compliance, and any partnerships or additional trial initiations. Integration progress following the Kira deal is another near-term marker of execution.
Risks to Watch
Despite the cash infusion, risks remain substantial. Clinical-stage biotech carries binary trial risk, and briquilimab must still demonstrate durable efficacy and safety across larger studies. The convertible preferred financing and all-stock acquisition imply potential dilution for common shareholders. A sub-$1 price keeps Nasdaq listing compliance in focus. Integration of Kira, execution on a broadened pipeline, and the long path to any eventual regulatory approval all add uncertainty.
A Company Reshaped by Dealmaking
Jasper Therapeutics is no longer simply a beaten-down microcap awaiting a bounce; it is a recapitalized, merged immunology company with a multi-year cash runway and a lead asset in chronic spontaneous urticaria. With the recent price move lacking a clear catalyst, investors may focus on clinical progress, integration, and how the company manages its Nasdaq listing.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...